Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis.
HIV
adherence
pharmacokinetics
pre-exposure prophylaxis
Journal
AIDS research and human retroviruses
ISSN: 1931-8405
Titre abrégé: AIDS Res Hum Retroviruses
Pays: United States
ID NLM: 8709376
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
pubmed:
17
11
2020
medline:
19
8
2021
entrez:
16
11
2020
Statut:
ppublish
Résumé
Tenofovir diphosphate (TFV-DP) concentrations measured with dried blood spots (DBS) can be used to classify adherence to emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP). A TFV-DP of 700 fmol/punch was previously associated with high PrEP efficacy, and was estimated to represent ≥4 doses/week on average. However, interindividual variability in TFV-DP concentrations may lead to adherence misclassification and decrease the precision of adherence-efficacy relationships. The purpose of this analysis was to evaluate sources of TFV-DP variability to improve the precision of TFV-DP for adherence assessments by incorporating individual characteristics. Data and samples from a 36-week study of TFV-DP in DBS, collected biweekly, among 48 HIV-negative volunteers (25 Females/26 Caucasian/10 African American/14 Hispanic) receiving F/TDF at 33%, 67%, and 100% of daily dosing under directly observed therapy were used for analysis. The simplest pharmacokinetic model to describe TFV-DP accumulation with acceptable performance was a one-compartment constant input model. Covariates, including laboratory values and demographics were ranked in importance of their association with
Identifiants
pubmed: 33191774
doi: 10.1089/AID.2020.0108
pmc: PMC8213008
doi:
Substances chimiques
Anti-HIV Agents
0
Emtricitabine
G70B4ETF4S
Banques de données
ClinicalTrials.gov
['NCT02022657']
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
421-428Subventions
Organisme : NIAID NIH HHS
ID : R01 AI122298
Pays : United States
Organisme : NIAID NIH HHS
ID : K23 AI104315
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001082
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI106499
Pays : United States
Références
Curr HIV/AIDS Rep. 2018 Feb;15(1):49-59
pubmed: 29380227
Ann Pharmacother. 2002 Sep;36(9):1331-6
pubmed: 12196047
Lancet HIV. 2017 Sep;4(9):e402-e410
pubmed: 28747274
J Pharmacokinet Biopharm. 1996 Jun;24(3):265-82
pubmed: 8970015
Clin Pharmacol Ther. 2014 Feb;95(2):154-67
pubmed: 24193171
PLoS One. 2016 Nov 10;11(11):e0165505
pubmed: 27832147
J Acquir Immune Defic Syndr. 2019 Nov 1;82(3):245-251
pubmed: 31343455
Antimicrob Agents Chemother. 2011 Nov;55(11):5294-9
pubmed: 21896913
AIDS Res Hum Retroviruses. 2013 Nov;29(11):1443-50
pubmed: 23600365
N Engl J Med. 2015 Dec 3;373(23):2237-46
pubmed: 26624850
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
Am J Health Syst Pharm. 2001 Jun 15;58(12):1126-32
pubmed: 11449856
Pharm Res. 1999 May;16(5):709-17
pubmed: 10350015
N Engl J Med. 2015 Feb 5;372(6):509-18
pubmed: 25651245
Pharmacogenomics. 2009 Oct;10(10):1675-85
pubmed: 19842939
J Pharm Biomed Anal. 2016 Apr 15;122:16-20
pubmed: 26829517
N Engl J Med. 2012 Aug 2;367(5):411-22
pubmed: 22784040
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
AIDS Res Hum Retroviruses. 2013 Feb;29(2):384-90
pubmed: 22935078
Br J Clin Pharmacol. 2018 Jul;84(7):1525-1534
pubmed: 29522646
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29038282
Basic Clin Pharmacol Toxicol. 2005 Mar;96(3):225-7
pubmed: 15733218
Antimicrob Agents Chemother. 2017 Feb 23;61(3):
pubmed: 27956420
AIDS Res Hum Retroviruses. 2020 Mar;36(3):173-175
pubmed: 31204866
Value Health. 2003 Sep-Oct;6(5):566-73
pubmed: 14627063
Nature. 2004 May 27;429(6990):464-8
pubmed: 15164072
J Pharmacokinet Pharmacodyn. 2004 Apr;31(2):109-34
pubmed: 15379381
Antimicrob Agents Chemother. 2005 Aug;49(8):3361-6
pubmed: 16048948
J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):298-303
pubmed: 18398970
AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):981-991
pubmed: 27526873
Curr Opin HIV AIDS. 2016 Jan;11(1):10-7
pubmed: 26633638
J Clin Pharmacol. 2015 Jun;55(6):629-38
pubmed: 25581815
AIDS Res Hum Retroviruses. 2018 Oct;34(10):835-837
pubmed: 30047286
AIDS. 2012 Apr 24;26(7):F13-9
pubmed: 22333749
Lancet Infect Dis. 2014 Sep;14(9):820-9
pubmed: 25065857
J Antimicrob Chemother. 2020 Jun 1;75(6):1591-1598
pubmed: 32211787
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5379-86
pubmed: 27353269
N Engl J Med. 2005 Aug 4;353(5):487-97
pubmed: 16079372
J Antimicrob Chemother. 2019 Aug 1;74(8):2352-2359
pubmed: 31093649
J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Jan 2;830(1):6-12
pubmed: 16269276